Global Blood Therapeutics (GBT) Stock Analysis

What Global Blood Therapeutics does

Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical firm dedicated to discovering, developing, and providing therapies for patients suffering from sickle cell disease (SCD) who currently lack adequate treatment options. Its marketed product, Oxbryta tablets, offers a once-daily, oral treatment for SCD. Furthermore, GBT is conducting a Phase IIa clinical trial to assess the safety and pharmacokinetic profile of single and multiple doses of Oxbryta in younger SCD patients, including adolescents and children. In its development pipeline, inclacumab stands as a primary candidate – a novel human monoclonal antibody currently undergoing Phase IIIa clinical trials. This investigational drug aims to diminish the occurrence of painful vaso-occlusive crises and subsequent hospitalizations. Also in early-stage development (Phase I) is GBT601, a compound designed to inhibit hemoglobin polymerization. The company holds a licensing and collaborative agreement with Syros Pharmaceuticals, Inc. focused on identifying, advancing, and commercializing treatments for both SCD and beta thalassemia. Additionally, GBT collaborates with Sanofi S.A. on two separate early-stage research initiatives targeting SCD. Established in 2011, Global Blood Therapeutics, Inc. maintains its headquarters in South San Francisco, California.

Key metrics

ETFs linked to GBT

Broad-market and Healthcare sector ETFs an investor holding Global Blood Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GBT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Global Blood Therapeutics?

Global Blood Therapeutics trades under the ticker GBT on NASDAQ.

Which exchange is GBT listed on?

GBT is listed on NASDAQ.

What sector does Global Blood Therapeutics operate in?

Global Blood Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GBT in a portfolio?

PortView shows GBT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.